Anton Devyaterikov

Mr. Anton Devyaterikov


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2026 in Microbiology Research
Verified
Journal Article
Open access
PDF file
ADAnton Devyaterikov
Anton Devyaterikov
NPNatalia V. Palyanova
Natalia V. Palyanova
APAndrey Palyanov
Andrey Palyanov
AKAndrey Komissarov
Andrey Komissarov
ISIvan Sobolev
Ivan Sobolev
ASAlexander M. Shestopalov
Alexander M. Shestopalov
Recombination is one of the mechanisms driving SARS-CoV-2 evolution and can generate genomes with novel combinations of characteristics inherited from parental lineages. We analyzed a total of 1963 genomes available SARS-CoV-2 genome sequences collected in the south of Western Siberia between March 2020 and 5 May 2023. Initial screening with Nextclade identified five potentially recombinant genomes. The consensus assemblies were re-examined by the originating laboratories and the absence of co-infection was confirmed. Recombinant origin was assessed with RecombinHunt and independently evaluated with 3SEQ and RDP5. EPI_ISL_11742584 was excluded because of numerous undetermined nucleotides. For EPI_ISL_15919275 the laboratory of origin did not confirm the reproducibility of the build. EPI_ISL_20438394 contained BA.2.35-like and XBB.3.1-like components but the signal did not survive correction for multiple comparisons. Recombination was confirmed for two sequences. EPI_ISL_17317906 presumably originated from CR.1-like and XBB.1.15-like lineages and was assigned to the recombinant lineage XBV. EPI_ISL_16287253 carried a BA.2-derived segment on a BA.1-derived background. These findings indicate that automated classification should be followed by statistical validation, verification of genome assembly quality and the confirmed absence of co-infection. Incomplete and uneven genomic surveillance may still limit reconstruction of the exact origins of rare recombinant variants.